Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia

L Andersson, M Scharin Täng, A Lundqvist… - Cardiovascular …, 2015 - academic.oup.com
L Andersson, M Scharin Täng, A Lundqvist, M Lindbom, I Mardani, P Fogelstrand…
Cardiovascular research, 2015academic.oup.com
Aims In myocardial ischaemia, vascular endothelial growth factor (VEGF) induces
permeability by activating a signalling pathway that includes VEGF receptor 2 (VEGFR2),
resulting in increased oedema and inflammation and thereby expanding the area of tissue
damage. In this study, we investigated the role of receptor-interacting protein 2 (Rip2) in
VEGF signalling and myocardial ischaemia/reperfusion injury. Methods and results To
determine whether Rip2 has a role in VEGF signalling, we used cultured endothelial cells in …
Aims
In myocardial ischaemia, vascular endothelial growth factor (VEGF) induces permeability by activating a signalling pathway that includes VEGF receptor 2 (VEGFR2), resulting in increased oedema and inflammation and thereby expanding the area of tissue damage. In this study, we investigated the role of receptor-interacting protein 2 (Rip2) in VEGF signalling and myocardial ischaemia/reperfusion injury.
Methods and results
To determine whether Rip2 has a role in VEGF signalling, we used cultured endothelial cells in which Rip2 was or was not inactivated. In Rip2-deficient endothelial cells, stimulation with VEGF resulted in more rapid kinetics of VEGFR2 phosphorylation than in control cells. Rip2 deficiency also enhanced VEGF-induced activation of ERK1/2, suggesting an increased propensity for endothelial permeability. In a mouse model of myocardial ischaemia, Rip2 deficiency resulted in enhanced vascular permeability, increased oedema and expanding area of myocardial damage, and markedly reduced heart function after long-term follow-up.
Conclusion
Our results show that Rip2 modifies VEGF-induced signalling and vascular permeability in myocardial ischaemia. These findings indicate that Rip2 may be a promising novel therapeutic target to reduce excess vascular permeability in ischaemic heart disease.
Oxford University Press